Drug Type Small molecule drug |
Synonyms N4,N6-bis(4-bromophenyl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-4,6-diamine |
Target |
Action inhibitors |
Mechanism PBP2a inhibitors(penicillin-binding protein 2a inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| MRSA - Methicillin resistant Staphylococcus aureus infection | Preclinical | United States | 16 Oct 2025 |





